Brief: Synthaverse Gets Marketing Authorization For Onko BCG In Serbia
15/05/2026 06:42
May 15 (Reuters) - Synthaverse SA SVEP.WA: SAID ON THURSDAY IT HAS RECEIVED MARKETING AUTHORIZATION FOR ONKO BCG MEDICINAL PRODUCT IN SERBIA APPLICATION FOR OBTAINING MARKETING AUTHORIZATION WAS SUBMITTED BY CORAPHARM, UNDER THE LICENSE GRANTED BY SYNTHAVERSE PLANS TO CONTINUE GLOBAL REGULATORY AND COMMERCIAL EXPANSION FOR BCG PRODUCTS Source text for Workspace: nEM1Cz2fXa Further company coverage: SVEP.WA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Synthaverse SA
See all newsBrief: Synthaverse EGM To Vote On Share Capital Increase Via Series X Share Issue
Brief: Synthaverse Gets 45 Mln Zloty Loan From Polish Agency For Enterprise Development For Debt Refinancing
Brief: Synthaverse Receives Registration Certificate For Onko BCG Product In Paraguay Under Partnership With Blau
Brief: Synthaverse H1 Net Loss At 6.4 Mln Zlotys
Brief: Synthaverse Gets Poland's GIF Decision Extending Manufacturing For New Immunological Products Facility